Funding Rounds
BioVersys

BioVersys Series C (2024, $13M)

BioVersys

Novel antiobiotic researcher to fight antimicrobial resistance.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series C

Raised Amount: $13.57M

Raised Date: 2024-07-01

Investors